The Effect of Mesenchymal Stromal Cells on the Mortality of Patients with Sepsis and Septic Shock: A Promising Therapy

Purpose. Sepsis and septic shock are the major causes of death in intensive care units. This study aimed to evaluate the clinical safety and efficacy of mesenchymal stem cells (MSCs) in sepsis and septic shock patients. Methods. Ten patients were enrolled in the study. Adipose-derived MSC infusions...

Full description

Saved in:
Bibliographic Details
Main Authors: Emine Alp, Zeynep Burcin Gonen, Kursat Gundogan, Aliye Esmaoglu, Leylagul Kaynar, Aysun Cetin, Musa Karakukcu, Mustafa Cetin, Gamze Kalin, Mehmet Doganay
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Emergency Medicine International
Online Access:http://dx.doi.org/10.1155/2022/9222379
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849395414672867328
author Emine Alp
Zeynep Burcin Gonen
Kursat Gundogan
Aliye Esmaoglu
Leylagul Kaynar
Aysun Cetin
Musa Karakukcu
Mustafa Cetin
Gamze Kalin
Mehmet Doganay
author_facet Emine Alp
Zeynep Burcin Gonen
Kursat Gundogan
Aliye Esmaoglu
Leylagul Kaynar
Aysun Cetin
Musa Karakukcu
Mustafa Cetin
Gamze Kalin
Mehmet Doganay
author_sort Emine Alp
collection DOAJ
description Purpose. Sepsis and septic shock are the major causes of death in intensive care units. This study aimed to evaluate the clinical safety and efficacy of mesenchymal stem cells (MSCs) in sepsis and septic shock patients. Methods. Ten patients were enrolled in the study. Adipose-derived MSC infusions were given (1 × 106/kg, on the 1st, 3rd, 5th, 7th, and 9th days of therapy) together with standard therapy. Before the MSC applications, blood samples were collected for cytokine assessment (TNF-α, IFN-γ, IL-2, IL-4, IL-6, IL-10). The clinical and laboratory improvements were recorded and compared with control groups selected retrospectively. The clinical trial was registered on 16.03.2022 with the registration number NCT05283317. Results. In the study group, the ages of patients ranged from 22 to 68 years, and APACHE II scores ranged from 14 to 42. In the control group, ages ranged from 22 to 80 years and their APACHE II scores were between 14–35. The survival rate in the study group was 100% on the 14th day whereas it was 70% on the 28th day. A significant decrease in the SOFA score (adjusted), clinical, and laboratory improvements were observed during the MSC administration. However, no significant cytokine level changes were observed. In the control group, the survival rate of 20 patients was 70% on the 14th day, whereas 60% was on the 28th day. While deaths were observed in the control group in the first week of treatment, deaths in the MSCs group were observed between the 15th and 28th days. Conclusion. MSCs treatment may have a positive impact on the survival rates of sepsis during the early phase. However, further randomized controlled studies with a large group of patients are needed. Trial Registration. This trial is registered with ClinicalTrials.gov Identifier: NCT05283317.
format Article
id doaj-art-ab81c4fe4629412785a3ec1f90ae8f73
institution Kabale University
issn 2090-2859
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Emergency Medicine International
spelling doaj-art-ab81c4fe4629412785a3ec1f90ae8f732025-08-20T03:39:37ZengWileyEmergency Medicine International2090-28592022-01-01202210.1155/2022/9222379The Effect of Mesenchymal Stromal Cells on the Mortality of Patients with Sepsis and Septic Shock: A Promising TherapyEmine Alp0Zeynep Burcin Gonen1Kursat Gundogan2Aliye Esmaoglu3Leylagul Kaynar4Aysun Cetin5Musa Karakukcu6Mustafa Cetin7Gamze Kalin8Mehmet Doganay9Department of Infectious Diseases and Clinical MicrobiologyOral and Maxillofacial SurgeryMedical Intensive Care UnitDepartment of Anesthesiology and ReanimationBone Marrow Transplant and Stem Cell UnitDepartment of BiochemistryDivision of Pediatric Hematology and OncologyBone Marrow Transplant and Stem Cell UnitDepartment of Infectious Diseases and Clinical MicrobiologyDepartment of Infectious DiseasesPurpose. Sepsis and septic shock are the major causes of death in intensive care units. This study aimed to evaluate the clinical safety and efficacy of mesenchymal stem cells (MSCs) in sepsis and septic shock patients. Methods. Ten patients were enrolled in the study. Adipose-derived MSC infusions were given (1 × 106/kg, on the 1st, 3rd, 5th, 7th, and 9th days of therapy) together with standard therapy. Before the MSC applications, blood samples were collected for cytokine assessment (TNF-α, IFN-γ, IL-2, IL-4, IL-6, IL-10). The clinical and laboratory improvements were recorded and compared with control groups selected retrospectively. The clinical trial was registered on 16.03.2022 with the registration number NCT05283317. Results. In the study group, the ages of patients ranged from 22 to 68 years, and APACHE II scores ranged from 14 to 42. In the control group, ages ranged from 22 to 80 years and their APACHE II scores were between 14–35. The survival rate in the study group was 100% on the 14th day whereas it was 70% on the 28th day. A significant decrease in the SOFA score (adjusted), clinical, and laboratory improvements were observed during the MSC administration. However, no significant cytokine level changes were observed. In the control group, the survival rate of 20 patients was 70% on the 14th day, whereas 60% was on the 28th day. While deaths were observed in the control group in the first week of treatment, deaths in the MSCs group were observed between the 15th and 28th days. Conclusion. MSCs treatment may have a positive impact on the survival rates of sepsis during the early phase. However, further randomized controlled studies with a large group of patients are needed. Trial Registration. This trial is registered with ClinicalTrials.gov Identifier: NCT05283317.http://dx.doi.org/10.1155/2022/9222379
spellingShingle Emine Alp
Zeynep Burcin Gonen
Kursat Gundogan
Aliye Esmaoglu
Leylagul Kaynar
Aysun Cetin
Musa Karakukcu
Mustafa Cetin
Gamze Kalin
Mehmet Doganay
The Effect of Mesenchymal Stromal Cells on the Mortality of Patients with Sepsis and Septic Shock: A Promising Therapy
Emergency Medicine International
title The Effect of Mesenchymal Stromal Cells on the Mortality of Patients with Sepsis and Septic Shock: A Promising Therapy
title_full The Effect of Mesenchymal Stromal Cells on the Mortality of Patients with Sepsis and Septic Shock: A Promising Therapy
title_fullStr The Effect of Mesenchymal Stromal Cells on the Mortality of Patients with Sepsis and Septic Shock: A Promising Therapy
title_full_unstemmed The Effect of Mesenchymal Stromal Cells on the Mortality of Patients with Sepsis and Septic Shock: A Promising Therapy
title_short The Effect of Mesenchymal Stromal Cells on the Mortality of Patients with Sepsis and Septic Shock: A Promising Therapy
title_sort effect of mesenchymal stromal cells on the mortality of patients with sepsis and septic shock a promising therapy
url http://dx.doi.org/10.1155/2022/9222379
work_keys_str_mv AT eminealp theeffectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT zeynepburcingonen theeffectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT kursatgundogan theeffectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT aliyeesmaoglu theeffectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT leylagulkaynar theeffectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT aysuncetin theeffectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT musakarakukcu theeffectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT mustafacetin theeffectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT gamzekalin theeffectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT mehmetdoganay theeffectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT eminealp effectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT zeynepburcingonen effectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT kursatgundogan effectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT aliyeesmaoglu effectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT leylagulkaynar effectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT aysuncetin effectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT musakarakukcu effectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT mustafacetin effectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT gamzekalin effectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy
AT mehmetdoganay effectofmesenchymalstromalcellsonthemortalityofpatientswithsepsisandsepticshockapromisingtherapy